Medical University of South Carolina

Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director

Retrieved on: 
Wednesday, November 1, 2023
Citadel, OCUP, Applied economics, Science, Military, Johns Hopkins University, Ophthalmology, Dermatology, Medicine, Medical University of South Carolina, Biochemistry, Acquisition, Diabetic retinopathy, Drug development, Economics, Growth, Clemson University, Partnership, Interim, Chemistry, Medical school, Patient, Retina, POS, Pharmaceutical industry, Management

Dr. Magrath succeeds Rick Rodgers, M.B.A., Interim Chief Executive Officer and President since April 2023.

Key Points: 
  • Dr. Magrath succeeds Rick Rodgers, M.B.A., Interim Chief Executive Officer and President since April 2023.
  • Mr. Rodgers will remain on the company’s Board of Directors.
  • “We are thrilled to have Dr. Magrath, a highly accomplished pharmaceutical executive with extensive business, financial, and medical expertise, join Ocuphire as Chief Executive Officer,” said Cam Gallagher, Chairman of Ocuphire Pharma’s Board of Directors.
  • Prior to Lexitas, Dr. Magrath served as Medical Director to Hovione Pharmaceuticals, LLC, responsible for developing and advancing the company’s proprietary drugs in dermatology, ophthalmology and respiratory.

Vesica Health Appoints Distinguished Urologic Oncologist Dr. William T. Lowrance to Chief Medical Officer

Retrieved on: 
Tuesday, October 31, 2023
Education minister, Harvard School of Dental Medicine, Survival, Huntsman Cancer Institute, Lee University, Hematuria, MPH, American Urological Association, Public health, Master of Business Administration, Hope, Memorial Sloan Kettering Cancer Center, Medical degree, Prostate cancer, Medical University of South Carolina, Bladder cancer, Bon, MBA, Health, Vesica, Memorial, Disease, Risk, Business administration, Business, University, Public, David Eccles School of Business, Medical school, HEALTH, Lowrance Electronics, Liquid biopsy, Patient, Diagnosis, Associate, Vanderbilt University Medical Center, Harvard T.H. Chan School of Public Health, Pharmaceutical industry, Nursing, Urology, MD, Chemistry

Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a practicing urologic oncologist, treating patients and conducting clinical trials.

Key Points: 
  • Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a practicing urologic oncologist, treating patients and conducting clinical trials.
  • "I have devoted my career to researching and treating urologic cancers, striving to improve patient care and ultimately, survival," said Dr. William T. Lowrance, Chief Medical Officer of Vesica Health.
  • Dr. Lowrance is an attending urologic oncologist at Bon Secours Mercy Health, specializing in the treatment of urologic malignancies, with a focus on bladder cancer.
  • While serving as the Chief Medical Officer of Vesica Health, Dr. Lowrance will continue his medical practice at Bon Secours Mercy Health.

Health systems and executives receive recognition for their notable impact on health care in 2023

Retrieved on: 
Monday, October 30, 2023
Los Alamos National Laboratory, Intelligence, Castell, Health, Lightning, NEXT Woman of the Year awards, Gillette Children's Specialty Healthcare, CIO, Meritas, Marketing, Partnership, Gillette, Breast cancer, Noteworthy, SAN, Patient satisfaction, Brain, Medical school, Intermountain Health, Movement, Patient, MUSC, Medical University of South Carolina, Nursing care plan, Automation, Nursing, Hospital, Pharmaceutical industry, Notability

SAN MATEO, Calif., Oct. 30, 2023 /PRNewswire/ -- Notable, the leading automation platform for patient engagement and staff workflows, unveiled the 2023 recipients of the Notable Impact Awards, which recognize health systems and executive champions who are driving technology-led transformation. With the many challenges facing health care, it can be easy to overlook the fresh thinking, bold strategies, courageous leadership and technological innovation that are helping to transform the industry from the inside out.

Key Points: 
  • "We have a lofty mission – to simplify and optimize healthcare for humanity," said Pranay Kapadia, CEO and co-founder at Notable.
  • We partner with health system leaders and visionaries to work together and do something that changes people's lives for the better.
  • This year's Notable Impact Award winners are shining examples of where we've been able to do just that."
  • The Notable Impact Awards are unveiled at Noteworthy, an annual executive retreat for healthcare leaders and changemakers.

CurvaFix to Host Industry Session at Orthopaedic Trauma Association Annual Meeting; Technology Featured in Poster Presentation

Retrieved on: 
Wednesday, October 18, 2023
Health, Medical Devices, Surgery, Other Health, Clinical Trials, Research, Science, Anatomy, Pelvic fracture, Session, Ageing, FFP, OTA, Trial of the century, University of Missouri, OU Health, University Medical Center, Seattle Convention Center, Bone fracture, Medical University of South Carolina, Multimedia, Surgeon, Mobility, University, Osteoporosis, Medical school, Patient, Pain, Dentistry, Medical device, Pelvis

CurvaFix, Inc. , a developer of medical devices that delivers stable fixation for curved anatomy and poor bone, has announced that it will host an Industry Session at the 39th annual meeting of the Orthopaedic Trauma Association ( OTA ), Oct. 18-21 in Seattle.

Key Points: 
  • CurvaFix, Inc. , a developer of medical devices that delivers stable fixation for curved anatomy and poor bone, has announced that it will host an Industry Session at the 39th annual meeting of the Orthopaedic Trauma Association ( OTA ), Oct. 18-21 in Seattle.
  • View the full release here: https://www.businesswire.com/news/home/20231018357859/en/
    CurvaFix is hosting an Industry Session at the 39th annual meeting of the Orthopaedic Trauma Association (OTA), Oct. 18-21 in Seattle, highlighting how surgeons are using the CurvaFix Implant for complex pelvic morphology, periprosthetic fracture, and fragility fractures of the pelvis.
  • (Graphic: Business Wire)
    CurvaFix also announced that a poster by Amir Matityahu, M.D., and additional authors outlining the results from a multicenter study evaluating the CurvaFix Implant will be presented at the annual meeting.
  • The Industry Session will occur on Thursday, Oct. 19, 7:00 am – 7:50 am (PT) in room 3B at the Seattle Convention Center, Arch Bldg.

Charleston's Peninsula Cosmetic & Family Dentistry is Featured as a 2023 Top Patient Rated Dentist by Find Local Doctors

Retrieved on: 
Wednesday, October 18, 2023
Knowledge, AEGD, SCDA, Dental education throughout the world, Health, Pediatric dentistry, Twilight anesthesia, IV, United States Department of the Air Force, Journal of the American Dental Association, Physician, Medical University of South Carolina, Dentistry, CEREC, Postgraduate training in general dentistry, McPherson, Doctor, Dental care, Multimedia, College, Environment, ADA, Doctorate, Happiness, Dentist, American Academy, American Dental Association, Air force, Orthodontics, Medical school, Academy of General Dentistry, CBCT, Patient, Prisma Health Richland Hospital

CHARLESTON, S.C., Oct. 18, 2023 /PRNewswire-PRWeb/ -- When patients want to achieve the best smile, they choose the best dentist in Charleston. Peninsula Cosmetic & Family Dentistry delivers superior dental care for patients at their state-of-the-art clinic, offering a comfortable, relaxing environment. Find Local Doctors has recently recognized Peninsula Cosmetic & Family Dentistry due to the five-star ratings and reviews this clinic has earned from satisfied patients. Find Local Doctors is a trusted online directory that recognizes physicians and dentists who have earned exceptional feedback. Convenience and comfort are vital parts of what makes this comprehensive dentistry practice unique. The Peninsula Cosmetic & Family Dentistry team prides itself on providing the most modern, caring and comfortable dental care available. Their services are designed for long-term health and happiness, including cosmetic dentistry for a beautiful smile, preventative care for healthy teeth and gums, and restorative treatments to preserve or repair damaged teeth. From preventative cleanings and Invisalign® clear aligners to periodontal therapy and full mouth restorations, their professional team offers a wide range of dental services. Better yet, they offer sedation dentistry for those looking to receive extra support during their visit. Peninsula Cosmetic & Family Dentistry firmly believes that dentistry should be affordable, in addition to convenient, and are pleased to offer an in-house savings plan and flexible scheduling options.

Key Points: 
  • Peninsula Cosmetic & Family Dentistry delivers superior dental care for patients at their state-of-the-art clinic, offering a comfortable, relaxing environment.
  • Find Local Doctors has recently recognized Peninsula Cosmetic & Family Dentistry due to the five-star ratings and reviews this clinic has earned from satisfied patients.
  • The Peninsula Cosmetic & Family Dentistry team prides itself on providing the most modern, caring and comfortable dental care available.
  • Jenni Bollmann, Peninsula Cosmetic & Family Dentistry, (843) 507-5481, [email protected] , www.peninsuladentistry.net
    View original content to download multimedia: https://www.prweb.com/releases/charlestons-peninsula-cosmetic--family-de...

Clinical Study Conducted at Medical University of South Carolina Finds Synchrony Medical's LibAirty™ Airway Clearance System Highly Effective for Chronic Lung Disease Patients

Retrieved on: 
Wednesday, October 18, 2023
Synchrony, Standard of care, Trial of the century, Respiratory failure, Urinary tract infection, Medical University of South Carolina, Sheba Medical Center, Person-centered therapy, Mucus, Marketing, Medical school, Patient, MUSC, Medical device, Pharmaceutical industry

CHARLESTON, S.C. and OR YEHUDA, Israel, Oct. 18, 2023 /PRNewswire/ -- The results of a clinical study of Synchrony Medical's LibAirty™ Airway Clearance System showed that the system was twice as effective in clearing mucus from the lungs of patients with chronic lung disease when compared to the standard of care therapy. The findings were announced in an oral presentation at CHEST2023 in Honolulu, Hawaii.

Key Points: 
  • The study, led by Dr. Patrick A. Flume at the Medical University of South Carolina (MUSC), randomized patients to receive two treatments: LibAirty™ and the standard of care in random order.
  • The system was effective and well tolerated by all subjects, which suggests its potential to enhance clinical outcomes in airway clearance for patients with chronic respiratory disease," said Dr. Flume.
  • "Synchrony's vision is to improve respiratory therapy for patients living with chronic lung disease by bringing best practice respiratory therapy to their homes.
  • Daily airway clearance is essential for millions of patients living with chronic lung disease to prevent respiratory infections and costly hospitalizations.

Phil A. Wright to Lead Memorial Regional Hospital South (Hollywood, FL)

Retrieved on: 
Wednesday, October 4, 2023
Phil, Memorial Hermann Health System, AdventHealth Ocala, Medical school, Multimedia, U.S. News & World Report, Hospital, Medical University of South Carolina, Patient, Florida A&M University, Physician, Health, News, Nursing

HOLLYWOOD, Fla., Oct. 4, 2023 /PRNewswire-PRWeb/ -- Memorial Healthcare System has named Phil A. Wright, FACHE chief executive officer at Memorial Regional Hospital South. He joins a facility that was named one of the best rehabilitation hospitals in the nation by U.S. News & World Report.

Key Points: 
  • HOLLYWOOD, Fla., Oct. 4, 2023 /PRNewswire-PRWeb/ -- Memorial Healthcare System has named Phil A. Wright, FACHE chief executive officer at Memorial Regional Hospital South .
  • Wright is a graduate of both Florida A&M University and the Medical University of South Carolina, where he earned a master's degree in health administration.
  • At Memorial Regional Hospital South, he will oversee a 280-bed facility that offers a wide range of healthcare services in a compassionate, collaborative setting.
  • South Florida-based Memorial Healthcare System ( http://www.mhs.net ) is a national leader in quality care and patient, physician, and employee satisfaction.

Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Genetics, Radiology, Pharmaceutical, Biotechnology, SCC, Medical University of South Carolina, T2A, Head, ASTRO, MFS, ART, Medical school, Radiation therapy, Patient, Risk, Annual general meeting, American Society for Radiation Oncology, BWH, Society, Metastasis, Medical imaging, Brigham

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART).
  • The data will be shared in an oral presentation during the American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting, being held Oct. 1-4 in San Diego.
  • “When a patient’s risk of metastasis is unclear, tough decisions as to which treatment approaches to pursue become that much more difficult.
  • An intermediate risk population in which ART is often considered was defined as Brigham and Women’s Hospital (BWH) stage T2a or higher (n=489).

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
Research, Clinical Trials, Biotechnology, Biometrics, Health, General Health, Other Science, Science, Oncology, Interventional pulmonology, High, Critical care, Comparison, HT, Medical college, ORACLE, Cancer, Lung cancer, Medical school, DO, Medical University of South Carolina, MD, Learning, Medical College of Wisconsin, Annual general meeting, PET/CT, Medical device, Medical imaging

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi.
  • These presentations will provide new insight on the clinical utility and real-world impact of the Nodify CDT and Nodify XL2 tests in the comprehensive management of lung nodules.
  • Dr. Kurman, remarked, "The data we're presenting at CHEST 2023 underscores the transformative potential of the Nodify XL2 test in managing all types of lung nodules.
  • However, published data shows that the performance of PET/CT imaging alone is compromised in assessing small lung nodules for cancer.

Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit

Retrieved on: 
Monday, September 18, 2023
Pulmonary fibrosis, Clinical trial, Medical school, Medical University of South Carolina, MD, Medicine, Pharmaceutical industry

About Avalyn PharmaAvalyn is a biopharmaceutical company developing targeted therapeutics for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities, which restrict their use and dosing. Avalyn is developing a pipeline of inhaled therapeutics designed to reduce systemic exposure and deliver medication to the site of disease. AP01, Avalyn’s lead candidate, is a formulation of pirfenidone optimized for delivery via inhalation. In recent clinical studies of AP01 assessed in 150 individuals with different forms of pulmonary fibrosis – idiopathic (IPF) and progressive pulmonary fibrosis (PPF) -- AP01 demonstrated the potential to improve both efficacy and safety over existing therapy. More information can be found at www.avalynpharma.com.

Key Points: 
  • Seattle, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced that
    CEO Lyn Baranowski will lead a workshop during the annual Hanson & Wade IPF Summit on September 19, 2023.
  • Ms. Baranowski and Timothy Whelan, MD, a pulmonologist and professor of medicine at the Medical University of South Carolina, will facilitate a discussion with attending medical and industry professionals on clinical trial strategies that could be employed to improve the development of therapies for pulmonary fibrosis .
  • Topics will include the selection and optimization of drug delivery methods, the impact of dosing regimens and administration routes on clinical studies, and the impact formulations have on immunogenicity and compliance.
  • Location: Westin Boston Seaport in Boston, MA